塞来昔布联合标准辅助化疗对III期结肠癌无病生存的影响:CALGB/SWOG 80702随机临床试验
这项2×2析因设计3期试验纳入2526例III期结肠癌患者,比较在辅助FOLFOX化疗基础上加用塞来昔布400mg每日口服3年与安慰剂的疗效。
要点
- 在III期结肠癌标准辅助FOLFOX化疗基础上加用塞来昔布3年,未显著改善无病生存。
- 塞来昔布组高血压(任何级别)发生率14.6%,安慰剂组10.9%。
核心结论
- 在III期结肠癌患者中,与安慰剂相比,在标准辅助化疗基础上加用塞来昔布3年未显著改善无病生存。
研究设计与样本
- CALGB/SWOG 80702为2×2析因设计3期试验,在美国和加拿大654家社区和学术中心开展。
- 2010年6月至2015年11月共入组2526例III期结肠癌患者,随访至2020年8月10日。
- 患者随机接受辅助FOLFOX(每2周)3个月或6个月,并随机接受塞来昔布400mg每日口服3年(n=1263)或安慰剂(n=1261)。
- 主要终点为无病生存,从随机化至记录复发或任何原因死亡。
主要发现
- 2524例纳入主要分析,中位随访6年,塞来昔布组337例、安慰剂组363例发生复发或死亡。
- FOLFOX治疗期间高血压(任何级别)发生率塞来昔布组14.6% vs 安慰剂组10.9%,FOLFOX完成后肌酐≥2级升高发生率1.7% vs 0.5%。
关键数值与推荐
- 方案治疗依从性(接受塞来昔布或安慰剂超过2.75年或持续至复发、死亡或不可接受不良事件)塞来昔布组70.8%,安慰剂组69.9%。
临床怎么用
- 不推荐在III期结肠癌标准辅助FOLFOX化疗基础上常规加用塞来昔布以改善无病生存。
- 应用塞来昔布时需关注高血压和肾功能变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Aspirin and cyclooxygenase 2 (COX-2) inhibitors have been associated with a reduced risk of colorectal polyps and cancer in observational and randomized studies. The effect of celecoxib, a COX-2 inhibitor, as treatment for nonmetastatic colon cancer is unknown. OBJECTIVE: To determine if the addition of celecoxib to adjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) improves disease-free survival in patients with stage III colon cancer. DESIGN, SETTING, AND PARTICIPANTS: Cancer and Leukemia Group B (Alliance)/Southwest Oncology Group 80702 was a 2 × 2 factorial design, phase 3 trial conducted at 654 community and academic centers throughout the United States and Canada. A total of 2526 patients with stage III colon cancer were enrolled between June 2010 and November 2015 and were followed up through August 10, 2020. INTERVENTIONS: Patients were randomized to receive adjuvant FOLFOX (every 2 weeks) for 3 vs 6 months with or without 3 years of celecoxib (400 mg orally daily; n = 1263) vs placebo (n = 1261). This report focuses on the results of the celecoxib randomization. MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival, measured from the time of randomization until documented recurrence or death from any cause. Secondary end points included overall survival, adverse events, and cardiovascular-specific events. RESULTS: Of the 2526 patients who were randomized (mean [SD] age, 61.0 years [11 years]; 1134 women [44.9%]), 2524 were included in the primary analysis. Adherence with protocol treatment, defined as receiving celecoxib or placebo for more than 2.75 years or continuing treatment until recurrence, death, or unacceptable adverse events, was 70.8% for patients treated with celecoxib and 69.9% for patients treated with placebo. A total of 337 patients randomized to celecoxib and 363 to placebo experienced disease recurrence or died, and with 6 years' median follow-up, the 3-year disease-free survival was 76.3% for celecoxib-treated patients vs 73.4% for placebo-treated patients (hazard ratio [HR] for disease recurrence or death, 0.89; 95% CI, 0.76-1.03; P = .12). The effect of celecoxib treatment on disease-free survival did not vary significantly according to assigned duration of adjuvant chemotherapy (P for interaction = .61). Five-year overall survival was 84.3% for celecoxib vs 81.6% for placebo (HR for death, 0.86; 95% CI, 0.72-1.04; P = .13). Hypertension (any grade) occurred while treated with FOLFOX in 14.6% of patients in the celecoxib group vs 10.9% of patients in the placebo group, and a grade 2 or higher increase in creatinine levels occurred after completion of FOLFOX in 1.7% vs 0.5% of patients, respectively. CONCLUSIONS AND RELEVANCE: Among patients with stage III colon cancer, the addition of celecoxib for 3 years, compared with placebo, to standard adjuvant chemotherapy did not significantly improve disease-free survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01150045.
引用
- Meyerhardt JA, Shi Q, Fuchs CS, et al. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021. PMID: 33821899. doi:10.1001/jama.2021.2454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。